Latest Post | Page 584 of 1373 | IASbaba

SPEAK TO MENTOR - CALL NOW!

SUBSCRIBE

PLI Scheme for Promotion Of Domestic Manufacturing of Critical KSMS/Drug Intermediates and APIs

Part of: GS Prelims and GS-III – Economy

In news

Approvals have been accorded to 16 applicants under Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs) in the country.

Key takeaways

The setting up of these 16 plants will lead to investment of Rs.348.70 crore and employment generation of about 3,042 by the companies.
The commercial production shall commence from 1st April, 2023 onward.
The scheme has been launched by the Department of Pharmaceuticals for promotion of domestic manufacturing of KSMs/APIs.
This will be achieved by setting up greenfield plants with minimum domestic value addition

Do you know?

The Indian pharmaceutical industry is the 3rd largest in the world by volume.
However, India is significantly dependent on the import of basic raw materials, viz., Bulk Drugs that are used to produce medicines.
In some specific bulk drugs, the import dependence is 80 to 100%.

Your Name *

Your Email *

Subject

Comments *

Search now.....